IPP Bureau
Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
By IPP Bureau - March 10, 2026
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
By IPP Bureau - March 10, 2026
Germany will be the first launch market
KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units
By IPP Bureau - March 10, 2026
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US
By IPP Bureau - March 10, 2026
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
By IPP Bureau - March 10, 2026
The first of four planned modules at the new plant is expected to come online by summer 2026
Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
By IPP Bureau - March 10, 2026
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old
By IPP Bureau - March 10, 2026
Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy
Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India
By IPP Bureau - March 10, 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
By IPP Bureau - March 10, 2026
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer
By IPP Bureau - March 10, 2026
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
AbbVie reports promising early results for novel obesity therapy ABBV-295
By IPP Bureau - March 10, 2026
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
By IPP Bureau - March 10, 2026
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease
By IPP Bureau - March 10, 2026
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
